Sclerosing cholangitis is a chronic, autoimmune inflammatory liver disorder characterized by progressive narrowing and scarring of the bile ducts. The condition encompasses several distinct forms, including primary sclerosing cholangitis, IgG4-related sclerosing cholangitis, secondary sclerosing cholangitis, and neonatal presentations. A frequent association with inflammatory bowel disease, particularly ulcerative colitis, has been documented. The umbrella category also includes isolated neonatal sclerosing cholangitis and neonatal ichthyosis-sclerosing cholangitis syndrome among its recognized subtypes.

Documented manifestations include jaundice, fatigue, and malabsorption. Progressive disease may lead to cirrhosis and liver failure. The type and severity of symptoms vary among individuals and differ considerably across the distinct subtypes of the condition.

Sclerosing cholangitis is classified as an autoimmune inflammatory disorder affecting the biliary system. The precise triggers and underlying mechanisms driving bile duct inflammation are not fully understood. No causative genetic variants are certified in the knowledge packet for this condition; it is not caused by a single inherited genetic change, though specific neonatal genetic subtypes exist within the broader disease group.

Diagnosis involves evaluation of liver function and biliary anatomy. The condition may be identified in the neonatal period or later in life, depending on the specific subtype. Diagnostic criteria and approaches differ by subtype and clinical presentation. The condition is catalogued under Orphanet identifier 447771 and GARD identifier 21868.

No treatments are specifically FDA-approved for sclerosing cholangitis. Disease management centers on addressing symptoms, monitoring for complications, and treating associated inflammatory conditions. Liver transplantation is a recognized intervention for advanced disease. Several compounds have received orphan drug designation for primary sclerosing cholangitis, including Beta-Lapachone, a Conatus Pharmaceuticals compound, a Gilead Sciences compound, and 25HC3S from DURECT Corporation. All carry DESIGNATED status only and have not received FDA marketing approval.

The condition can be progressive, with potential advancement to cirrhosis and liver failure. The disease course varies considerably across subtypes, with neonatal presentations and IgG4-related forms having distinct natural histories from the primary form. Individual outcomes differ based on subtype, disease severity, and associated conditions.

Sclerosing cholangitis has a substantial and active clinical research landscape, with numerous ongoing clinical trials investigating new interventions. Active studies span drug therapy, procedural approaches, and medical device investigations, with both academic and commercial sponsors engaged. Ongoing trials include Phase 2 and Phase 3 investigations of therapeutic compounds such as elafibranor. Published research comprises a large body of review and meta-analysis literature, biomarker investigations, and recent trial-related publications across nearly 400 classified articles.